On September 16, 2020 Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, reported that the China National Intellectual Property Administration (CNIPA) issued a notice of allowance for a new patent application covering ALLOCETRA, the company’s immunotherapy product candidate (Press release, Enlivex Therapeutics, SEP 16, 2020, View Source [SID1234569023]). Upon issuance, the new patent will provide added intellectual property protection, including methods, uses and pharmaceutical compositions. The company expects that this new patent will be issued in China during the fourth quarter of 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ALLOCETRA has been designed to provide a novel immunotherapy mechanism of action that targets life-threatening clinical indications that are defined as "unmet medical needs", including organ dysfunction and acute multiple organ failure associated with Sepsis and COVID-19, as well as treating solid tumors by modulating such tumors’ microenvironment.